Temozolomide-based regimens for high O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status led to prolonged remission in a case of metastatic PC, highlighting the success of precision oncology [42]. The gene discussed is MGMT; the disease is pachyonychia congenita.